Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H. Res. 1331 Introduced in House (IH)]

<DOC>

119th CONGRESS
  2d Session
H. RES. 1331

Expressing support for the designation of June 1, 2026, through June 7, 
         2026, as ``Hidradenitis Suppurativa Awareness Week''.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              June 2, 2026

Mrs. Dingell (for herself and Mr. Joyce of Pennsylvania) submitted the 
following resolution; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                               RESOLUTION

 
Expressing support for the designation of June 1, 2026, through June 7, 
         2026, as ``Hidradenitis Suppurativa Awareness Week''.

Whereas Hidradenitis Suppurativa (in this resolution referred to as ``HS'') is a 
        chronic, inflammatory skin disease that affects approximately 3,300,000 
        people in the United States;
Whereas HS causes painful, boil-like nodules and abscesses anywhere on the body, 
        and can progress to form tunnels under the skin and cause extensive 
        scarring;
Whereas individuals with HS frequently suffer from 5 primary domains of physical 
        and emotional suffering, pain, drainage, odor, itching, and profound 
        psychological distress;
Whereas HS is associated with one of the highest completed suicide rates among 
        dermatological diseases, second only to melanoma;
Whereas 75 percent of individuals with HS are misdiagnosed or not diagnosed 
        until after age 25, missing critical windows for early intervention and 
        care;
Whereas delayed diagnosis contributes to worsening disease progression, higher 
        healthcare costs, avoidable emergency room visits, and unnecessary 
        procedures;
Whereas individuals are often diagnosed with HS in the prime of their lives, 
        affecting their ability to work, maintain relationships, and participate 
        fully in society;
Whereas there are currently only 3 biologic therapies approved by the Food and 
        Drug Administration for the treatment of HS;
Whereas additional research is urgently needed to develop new treatments, 
        understand the pathogenesis of the disease, identify biomarkers of HS, 
        and improve outcomes for HS patients;
Whereas Federal policy can play a critical role in improving access to biologic 
        therapies, wound care, and comprehensive care for HS patients; and
Whereas designating the first week of June as ``Hidradenitis Suppurativa 
        Awareness Week'' would increase public awareness, foster understanding, 
        and catalyze progress in diagnosing, treating, and ultimately curing HS: 
        Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) supports the designation of ``Hidradenitis Suppurativa 
        Awareness Week''; and
            (2) recognizes the importance of--
                    (A) increasing awareness and education about HS 
                among the public and health professionals;
                    (B) promoting timely and accurate diagnosis of HS 
                through improved screening and culturally competent 
                care;
                    (C) supporting biomedical research to better 
                understand HS pathogenesis, treatment efficacy, and 
                long-term outcomes;
                    (D) accelerating the development of effective 
                treatments and expanding access to existing therapies 
                for HS; and
                    (E) advancing policies that improve access to care 
                and quality of life for people living with HS and their 
                caregivers.
                                 <all>